Can’t say we are at all shocked with Novo Nordisk announcement that they are buying a controlling stake in BIOCORP for $164.5 million. Biocorp has been around forever and has collaborated with Novo in the past. It also goes along with Novo’s conversion from an insulin first to GLP-1 first insulin second company.
Give Novo some credit here for seeing the future. It’s just a matter of time before Tyler becomes a reality. Medtronic has the InPen while Lilly has their Tempo device and rumors have been swirling that Abbott will pull the trigger and . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.